SND1
Overview
SND1 (Staphylococcal nuclease domain-containing 1) is observed in the corpus as a fusion partner in BRAF fusions, identified in a tumor-agnostic genomic analysis of BRAF fusion-positive cancers.
Alterations observed in the corpus
- SND1 was identified as a 5’ fusion partner for BRAF among 82 unique partners observed across 52 histologies in a tumor-agnostic BRAF fusion cohort (n=nationwide retrospective analysis, MSK-IMPACT/MSK-Fusion) PMID:38922339.
- SND1 acts as a 5’ fusion partner in SND1/BRAF fusions detected in 3/484 (0.6%) papillary thyroid carcinomas (PTCs); these BRAF fusions are BVL (BRAFV600E-like expression) and mutually exclusive with RAS/EIF1AX point mutations, suggesting targetability with BRAF inhibitors. PMID:25417114
- SND1-BRAF fusion identified in 1 patient in a prospective MSK-IMPACT cohort of 860 metastatic LUAD patients; treated with BRAF+MEK combination therapy with no clinical benefit PMID:28336552.
Cancer types (linked)
- Not specifically linked to a single cancer type in the corpus; BRAF fusions involving SND1 were observed across diverse histologies PMID:38922339.
Co-occurrence and mutual exclusivity
- SND1-BRAF fusions co-occur with TP53 mutations (22% across all histologies) and other frequent co-alterations in BRAF fusion-positive tumors PMID:38922339.
Therapeutic relevance
- BRAF fusions are emerging actionable targets; MEK inhibitors and BRAF dimer blockers are under investigation for BRAF fusion-positive cancers PMID:38922339.
Open questions
- Clinical characteristics and response rates specific to SND1-BRAF fusions are not separately reported in the corpus PMID:38922339.
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:25417114
This page was processed by crosslinker on 2026-05-14. - PMID:28336552
This page was processed by wiki-cli on 2026-05-14.